Component
Parkinson disease UPDRS progression
Parkinson disease UPDRS progression. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Neither CoQ dose slowed UPDRS worsening versus placebo; the trial stopped for futility.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/coq10-research/24664227.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b1f301e82d4650432dab586db0be51f96e131f3c6084af9aebde932e8072676b", "start_char": 0, "end_char": 3023, "text_sha256": "b1f301e82d4650432dab586db0be51f96e131f3c6084af9aebde932e8072676b"}
- experimental_model
- Randomized double-blind phase III trial
- exposure
- CoQ10 1200 or 2400 mg/day; all groups received 1200 IU/day vitamin E
- limitations
- Vitamin E was a common background intervention; this comparison cannot identify its independent effect.
- nutrient_topic
- Coenzyme Q10 research collection; topical membership is not evidence of a direct dietary effect. · Coenzyme Q10 / CoQ10 redox system
- organism
- 600 early-Parkinson patients
- plain_language
- A plausible mitochondrial mechanism did not translate into slower Parkinson progression in this trial.
- primary_references
- [coq10-p24664227] A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014). https://pubmed.ncbi.nlm.nih.gov/24664227/ DOI: 10.1001/jamaneurol.2014.131
- tissue_or_cell_type
- UPDRS progression
Coenzyme Q10: biosynthesis, electron transfer, antioxidant recycling and nutrient interactions (2026-09-17) · lines 1217–1228
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind phase III trial · source_derived_draft · unverified_draft
### coq10-parkinson-null Neither CoQ dose slowed UPDRS worsening versus placebo; the trial stopped for futility. Condition category: normal nutrient_topic: Coenzyme Q10 research collection; topical membership is not evidence of a direct dietary effect. plain_language: A plausible mitochondrial mechanism did not translate into slower Parkinson progression in this trial. organism: 600 early-Parkinson patients tissue_or_cell_type: UPDRS progression experimental_model: Randomized double-blind phase III trial limitations: Vitamin E was a common background intervention; this comparison cannot identify its independent effect. exposure: CoQ10 1200 or 2400 mg/day; all groups received 1200 IU/day vitamin E evidence_span: {"source_cache": "artifacts/coq10-research/24664227.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b1f301e82d4650432dab586db0be51f96e131f3c6084af9aebde932e8072676b", "start_char": 0, "end_char": 3023, "text_sha256": "b1f301e82d4650432dab586db0be51f96e131f3c6084af9aebde932e8072676b"} [coq10-p24664227] A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014). https://pubmed.ncbi.nlm.nih.gov/24664227/ DOI: 10.1001/jamaneurol.2014.131
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.